GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Jenscare Scientific Co Ltd (HKSE:09877) » Definitions » Net Current Asset Value

Jenscare Scientific Co (HKSE:09877) Net Current Asset Value : HK$1.56 (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Jenscare Scientific Co Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Jenscare Scientific Co's net current asset value per share for the quarter that ended in Dec. 2024 was HK$1.56.

The historical rank and industry rank for Jenscare Scientific Co's Net Current Asset Value or its related term are showing as below:

HKSE:09877' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.1   Med: 7.99   Max: 31.03
Current: 5.46

During the past 5 years, the highest Price-to-Net-Current-Asset-Value Ratio of Jenscare Scientific Co was 31.03. The lowest was 2.10. And the median was 7.99.

HKSE:09877's Price-to-Net-Current-Asset-Value is ranked worse than
54.47% of 582 companies
in the Medical Devices & Instruments industry
Industry Median: 4.85 vs HKSE:09877: 5.46

Jenscare Scientific Co Net Current Asset Value Historical Data

The historical data trend for Jenscare Scientific Co's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jenscare Scientific Co Net Current Asset Value Chart

Jenscare Scientific Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Net Current Asset Value
0.95 2.28 2.13 2.78 1.54

Jenscare Scientific Co Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only 2.13 1.91 2.78 1.88 1.56

Competitive Comparison of Jenscare Scientific Co's Net Current Asset Value

For the Medical Devices subindustry, Jenscare Scientific Co's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jenscare Scientific Co's Price-to-Net-Current-Asset-Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Jenscare Scientific Co's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Jenscare Scientific Co's Price-to-Net-Current-Asset-Value falls into.


;
;

Jenscare Scientific Co Net Current Asset Value Calculation

Jenscare Scientific Co's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2024 is calculated as

Net Current Asset Value Per Share(A: Dec. 2024 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(732.268-118.097--15.811-0)/408.947
=1.54

Jenscare Scientific Co's Net Current Asset Value (NCAV) per share for the quarter that ended in Dec. 2024 is calculated as

Net Current Asset Value Per Share(Q: Dec. 2024 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(732.268-118.097--15.811-0)/404.879
=1.56

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Jenscare Scientific Co  (HKSE:09877) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Jenscare Scientific Co Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Jenscare Scientific Co's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Jenscare Scientific Co Business Description

Traded in Other Exchanges
N/A
Address
No. 777 Binhai 4th Road, Block 5, B Area, Hangzhou Bay New Area, Zhejiang Province, Ningbo, CHN
Jenscare Scientific Co Ltd is engaged in the manufacturing and research and development of medical devices. The company develops interventional products for the treatment of structural heart disease. The company's core products include LuX-Valve and Ken-Valve. LuX-Valve is a transcatheter tricuspid valve replacement system designed for patients with severe tricuspid regurgitation and high surgical risk. Ken-Valve is designed for the treatment of severe aortic regurgitation or combined with aortic stenosis. The company also develops product candidates for the treatment of mitral valve diseases and medical devices for the treatment of heart failure.
Executives
Lv Shiwen 2501 Other
Li Hui 2501 Other
Shanghai Shidi Industrial Development Co., Ltd. 2501 Other
Ningbo Linfeng Biotechnology Co., Ltd. 2101 Beneficial owner
Onez International Limited 2101 Beneficial owner
Pan Fei 2201 Interest of corporation controlled by you
Trident Trust Company (hk) Limited 2301 Trustee
Trinity Elite I International Limited 2201 Interest of corporation controlled by you
Ningbo Dixiang Venture Capital Co., Ltd. 2201 Interest of corporation controlled by you
Shanghai Jiachen Investment Co.,ltd 2201 Interest of corporation controlled by you
Ningbo Sangdi Investment Management L.p. (limited Partnership) 2101 Beneficial owner
Hainan Yize Medical Technology Co., Limited 2201 Interest of corporation controlled by you
Hainan Maidi Enterprise Management L.p. (limited Partnership) 2101 Beneficial owner
Hainan Hualing Investment L.p. (limited Partnership) 2101 Beneficial owner
Hangzhou Chende Investment Partnership (limited Partnership) 2101 Beneficial owner

Jenscare Scientific Co Headlines

No Headlines